Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Fundamental Analysis

NASDAQ:ALXO - Nasdaq - US00166B1052 - Common Stock - Currency: USD

0.4058  -0.05 (-10.34%)

After market: 0.4157 +0.01 (+2.44%)

Fundamental Rating

1

Overall ALXO gets a fundamental rating of 1 out of 10. We evaluated ALXO against 555 industry peers in the Biotechnology industry. ALXO may be in some trouble as it scores bad on both profitability and health. ALXO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALXO has reported negative net income.
ALXO had a negative operating cash flow in the past year.
ALXO had negative earnings in each of the past 5 years.
In the past 5 years ALXO always reported negative operating cash flow.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -107.44%, ALXO is not doing good in the industry: 78.14% of the companies in the same industry are doing better.
With a Return On Equity value of -147.73%, ALXO is not doing good in the industry: 62.54% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -107.44%
ROE -147.73%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

ALXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALXO has been increased compared to 1 year ago.
Compared to 5 years ago, ALXO has more shares outstanding
Compared to 1 year ago, ALXO has a worse debt to assets ratio.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -10.08, we must say that ALXO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALXO (-10.08) is worse than 74.37% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that ALXO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.11, ALXO is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -10.08
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.42 indicates that ALXO has no problem at all paying its short term obligations.
The Current ratio of ALXO (5.42) is comparable to the rest of the industry.
A Quick Ratio of 5.42 indicates that ALXO has no problem at all paying its short term obligations.
ALXO has a Quick ratio (5.42) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.42
Quick Ratio 5.42
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ALXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.60%, which is quite impressive.
EPS 1Y (TTM)33.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.65% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.04%
EPS Next 2Y22.71%
EPS Next 3Y16.54%
EPS Next 5Y23.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2028 2029 2030 2031 2032 100M 200M 300M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALXO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ALXO's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.71%
EPS Next 3Y16.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALXO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (6/27/2025, 8:00:00 PM)

After market: 0.4157 +0.01 (+2.44%)

0.4058

-0.05 (-10.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners61.67%
Inst Owner Change-15.17%
Ins Owners1.42%
Ins Owner Change1.74%
Market Cap21.69M
Analysts81.67
Price Target2.65 (553.03%)
Short Float %13.41%
Short Ratio11.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.51%
Min EPS beat(2)-22.55%
Max EPS beat(2)19.52%
EPS beat(4)3
Avg EPS beat(4)6.93%
Min EPS beat(4)-22.55%
Max EPS beat(4)27.1%
EPS beat(8)5
Avg EPS beat(8)0.36%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-1.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.97%
PT rev (3m)-36.84%
EPS NQ rev (1m)-6.51%
EPS NQ rev (3m)3.57%
EPS NY rev (1m)-6.91%
EPS NY rev (3m)-2.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.44%
ROE -147.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.42
Quick Ratio 5.42
Altman-Z -10.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.83%
Cap/Depr(5y)2095.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.31%
EPS Next Y30.04%
EPS Next 2Y22.71%
EPS Next 3Y16.54%
EPS Next 5Y23.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.81%
EBIT Next 3Y17.54%
EBIT Next 5YN/A
FCF growth 1Y-11.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.11%
OCF growth 3YN/A
OCF growth 5YN/A